Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer

An HDM201, hdm2-p53 technology, applied in the combination of an HDM2-P53 interaction inhibitor and a BCL2 inhibitor, and the field of use in the treatment of cancer, can solve problems such as lack of efficacy and/or safety, and achieve a favorable therapeutic index, The effect of low morbidity

Pending Publication Date: 2021-07-30
NOVARTIS AG
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] Cancer monotherapies often suffer from lack of sustained efficacy and / or safety concerns

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
  • Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
  • Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0111] Example 1: HDM201 dosing regimen modeling

[0112] platelet model

[0113] Based on the population PK / PD data from clinical study CHDM201X2101, an AML patient platelet model was developed that recognizes that the disease affects the regulation of platelet production. The figure below illustrates the described model.

[0114]

[0115] Myeloid Blast Model

[0116] A bone marrow blast PKPD model was developed that recognizes a delayed effect, loss of effect over time that is recapitulated by the resistance component, and recognizes the impact of intensive administration to reduce resistance. The figure below illustrates the described model.

[0117]

[0118] Derivation of key metrics from simulated platelet and blast curves

[0119] The population PK / PD models of Example 1 and Example 2 were used to simulate time-dependent variation and inter-individual variation in PK, platelet and blast profiles.

[0120] The effect of changes in dosing regimen on thes...

example 2

[0215] Example 2: Preclinical Research

[0216] Example 2: In vivo pharmacology of HDM201 and venetoclax combination

[0217] In multiple AML patient-derived orthotopic models, HDM201 was shown to enhance the in vivo antitumor activity of the selective Bcl-2 inhibitor venetoclax. In mutant IDH1 / FLT3-ITD bearing mice, HDM201 treatment alone exhibited minimal anticancer activity (92% T / C, p>0.05). In contrast, HDM201 in combination with venetoclax induced complete tumor regression (-100% Reg), whereas only partial tumor regression was observed with venetoclax alone (-9% to -52% Reg). See Figures 8 and 9.

[0218] Consistent with observations in peripheral blood, by spleen weight and IDH1 R132H IHC staining of positive leukemic cells also observed depletion of leukemic cells in the spleen. HDM201 as a single agent resulted in modest reductions in spleen size and leukemic density. In contrast, HDM201 in combination with venetoclax resulted in almost complete depletion of le...

example 3

[0220] Example 3: Clinical Research

[0221] Rationale and Design of Dose / Regimen and Duration of Treatment of HDM201 in Combination with Venetoclax

[0222] This is a Phase 1b, multi-arm, open-label study of HDM201 in combination with venetoclax in subjects with AML or high-risk MDS.

[0223] For all subjects, TP53WT status must be characterized by at least the absence of mutations in exons 5, 6, 7, and 8.

[0224] Subjects will receive HDM201 in combination with venetoclax.

[0225] The venetoclax dose will be gradually increased (rising) over a period of 4 to 5 days to reach the target daily dose to be tested (400 or 600 mg), as shown in the diagram below:

[0226] Rise of venetoclax (RU) during cycle 1 (treatment arm 2: HDM201 + venetoclax)

[0227]

[0228] Once subjects have received the planned target daily dose, they will continue with that dose of venetoclax.

[0229] HDM201 doses can be escalated (see Table 3-1 for interim dose levels to be tested). Based...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax]. The present invention further relates to the use of said combination in the treament of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment.

Description

technical field [0001] The present invention relates to HDM2-p53 interaction inhibitor drug (S)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4 -Chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d] Imidazol-4-one [HDM201] and the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} Piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4 base)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2 , Combinations of 3-b]pyridin-5-yl)oxy]benzamide [venetoclax]. The invention further relates to the use of said combination in the treatment of cancer, especially hematological tumors. The invention further relates to dosages and administration regimens for this combination cancer therapy. Background technique [0002] HDM201 [0003] p53 is induced and activated by a number of potentially tumorigenic processes including aberrant growth signals, DNA damage, ultraviolet light, and protein kinase inhibitors (Millard M et al. Curr ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/506A61K31/635A61K39/395A61K45/06A61P35/02C07K16/28
CPCC07K16/2803C07K2317/24A61K2039/545A61K2039/54A61K39/3955A61K2039/505A61K31/506A61P35/02A61K45/06A61K31/635A61K31/706A61K2300/00C07K2317/56C07K2317/565C07K2317/92
Inventor N·格雷罗E·哈利洛维奇A·朱利翁C·麦勒王幼真
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap